Jasper Therapeutics, Inc. (JSPR) 股票分析

公司概述

Jasper Therapeutics, Inc. operates as a clinical-stage biotechnology firm dedicated to the development of novel therapeutics aimed at treating mast and hematopoietic stem cell driven diseases. The company functions within the broader healthcare sector, specifically focusing on the biotechnology industry where innovation in drug discovery is critical for advancing medical treatments. As of the latest data, the company possesses a market capitalization of $23.06 million and maintains an employee count of 22 individuals. These valuation and staffing figures indicate that Jasper Therapeutics is a small-cap entity with a relatively lean operational structure typical of early-stage biopharma companies that are still in the research and development phase rather than commercialization.

财务健康

The company reports no annual revenue under the trailing twelve months (TTM) metric, while recording a net income loss of $-75,801,000 and an EBITDA of $-80,527,000. The absence of revenue combined with significant net losses reveals a cost structure heavily weighted toward research and development expenses and operational burn, characteristic of pre-revenue biotechnology ventures. Furthermore, the company generated negative free cash flow totaling $-47,189,376, which signifies a substantial outflow of capital required to sustain operations and fund product candidates like briquilimab. All three reported margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated commercial sales to cover its direct costs or operating expenses. On the balance sheet, Jasper Therapeutics holds $28.69 million in cash against $1.24 million in debt, resulting in a debt-to-equity ratio of 29.75. Although the debt load exists, the significant cash reserve suggests the balance sheet is not leveraged in a distress manner, yet the high debt-to-equity ratio relative to equity indicates a capital structure reliant on equity financing rather than debt. The current ratio stands at 2.62, indicating that the company possesses sufficient current assets to cover its short-term liabilities more than twice over, suggesting adequate short-term liquidity despite the lack of operational cash generation. Return on Equity is reported at -230.3% and Return on Assets at -88.2%, metrics that reveal that the company is currently destroying value on an accounting basis due to accumulated losses, which is typical for clinical-stage firms but highlights the risk profile for shareholders waiting for a successful product launch.

估值评估

The trailing twelve-month P/E ratio is listed as N/A due to the lack of earnings, whereas the forward P/E is calculated at -0.49, a negative figure that implies earnings are expected to remain negative or that the market is pricing in future profitability that has not yet materialized in historical data. The price-to-book ratio is 5.56, indicating that the market values the company at a premium of 5.56 times its book value, which often reflects high expectations for the potential success of its pipeline assets. The price-to-sales ratio is N/A because there are no sales, and the EV/EBITDA stands at 0.06, a figure that suggests the enterprise value is extremely low relative to its EBITDA, often seen in companies with significant cash balances that offset valuation multiples. The stock has traded between a 52-week low of $0.65 and a 52-week high of $7.19, showing a wide trading range that reflects high investor sentiment volatility regarding the company's clinical milestones. With a beta of 3.20, the stock exhibits high price volatility relative to the broader market, meaning its price movements are expected to be 3.2 times more volatile than the market average, which increases both potential upside and downside risk for holders.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet achieved commercial sales to generate a growth trajectory to analyze. Consequently, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Because the company is non-dividend paying and currently unprofitable, it must reinvest all available earnings and cash flow into research and development to advance its lead product candidate rather than distributing income to shareholders. The overall growth and income profile is defined by a complete reliance on capital markets for funding expansion, with no current income generation or historical growth rates to reference for investors evaluating the risk-reward asymmetry of the asset.